These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 37416088)

  • 1. HIV remission trial investigators' attitudes towards risk and risk mitigation in trials that include treatment interruption.
    Okumu EA; Henderson GE; Golin C; Kuczynski K; Ormsby NQ; Peay HL
    J Virus Erad; 2023 Jun; 9(2):100331. PubMed ID: 37416088
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Attitudes About Analytic Treatment Interruption (ATI) in HIV Remission Trials with Different Antiretroviral Therapy (ART) Resumption Criteria.
    Peay HL; Rennie S; Cadigan RJ; Gwaltney A; Jupimai T; Phanuphak N; Kroon E; Colby DJ; Ormsby N; Isaacson SC; Vasan S; Sacdalan C; Prueksakaew P; Benjapornpong K; Ananworanich J; Henderson GE
    AIDS Behav; 2022 May; 26(5):1504-1516. PubMed ID: 34997386
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ethical and practical considerations for mitigating risks to sexual partners during analytical treatment interruptions in HIV cure-related research.
    Dubé K; Kanazawa J; Dee L; Taylor J; Campbell DM; Brown B; Johnson MO; Saberi P; Sauceda JA; Sugarman J; Peluso MJ
    HIV Res Clin Pract; 2021 Feb; 22(1):14-30. PubMed ID: 33757411
    [No Abstract]   [Full Text] [Related]  

  • 4. Central Nervous System Safety During Brief Analytic Treatment Interruption of Antiretroviral Therapy Within 4 Human Immunodeficiency Virus Remission Trials: An Observational Study in Acutely Treated People Living With Human Immunodeficiency Virus.
    Hellmuth J; Muccini C; Colby DJ; Kroon E; de Souza M; Crowell TA; Chan P; Sacdalan C; Intasan J; Benjapornpong K; Tipsuk S; Puttamaswin S; Chomchey N; Valcour V; Sarnecki M; Tomaka F; Krebs SJ; Slike BM; Jagodzinski LL; Dumrongpisutikul N; Sailasuta N; Samboju V; Michael NL; Robb ML; Vasan S; Ananworanich J; Phanuphak P; Phanuphak N; Paul R; Spudich S
    Clin Infect Dis; 2021 Oct; 73(7):e1885-e1892. PubMed ID: 32916708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Participant experiences in a combination HIV cure-related trial with extended analytical treatment interruption in San Francisco, United States.
    Dubé K; Ndukwe SO; Korolkova A; Dee L; Sugarman J; Sauceda JA
    HIV Res Clin Pract; 2024 Jan; 25(1):2312318. PubMed ID: 38348830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Perspectives on Analytical Treatment Interruptions in People Living with HIV and Their Health Care Providers in the Landscape of HIV Cure-Focused Studies.
    Lau JSY; Smith MZ; Allan B; Martinez C; Power J; Lewin SR; McMahon JH
    AIDS Res Hum Retroviruses; 2020 Apr; 36(4):260-267. PubMed ID: 31608648
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Understanding participant perspectives around HIV-1 cure-related studies involving antiretroviral analytical treatment interruptions in the United Kingdom.
    Lee MJ; Godakandaarachchi P; Collins S; Racz M; Sharp A; Fidler S; Fox J
    J Virus Erad; 2023 Dec; 9(4):100360. PubMed ID: 38188642
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Essential Need for Trust When Transmission Risk Cannot Be Eliminated in HIV-Remission Trials.
    Rennie S; Henderson G; Phanuphak N; Kuczynski K; Colby D; Ormsby N; Kroon E; Hsu D; Likhitwonnawut U; Vasan S; Sacdalan C; Jupimai T; Butterworth O; Peay H
    Ethics Hum Res; 2023; 45(4):2-15. PubMed ID: 37368521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Participant experiences in HIV cure-directed trial with an extended analytical treatment interruption in Philadelphia, United States.
    Bilger A; Plenn E; Barg FK; Rendle KA; Carter WB; Lamour-Harrington A; Jones N; Peterson B; Sauceda JA; Tebas P; Mounzer K; Metzger D; Montaner LJ; Dubé K
    HIV Res Clin Pract; 2023 Oct; 24(1):2267825. PubMed ID: 37837376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A collaborative, multidisciplinary approach to HIV transmission risk mitigation during analytic treatment interruption.
    Peluso MJ; Dee L; Campbell D; Taylor J; Hoh R; Rutishauser RL; Sauceda J; Deeks SG; Dubé K
    J Virus Erad; 2020 Feb; 6(1):34-37. PubMed ID: 32175090
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Considerations for Increasing Racial, Ethnic, Gender, and Sexual Diversity in HIV Cure-Related Research with Analytical Treatment Interruptions: A Qualitative Inquiry.
    Dubé K; Kanazawa J; Campbell C; Boone CA; Maragh-Bass AC; Campbell DM; Agosto-Rosario M; Stockman JK; Diallo DD; Poteat T; Johnson M; Saberi P; Sauceda JA
    AIDS Res Hum Retroviruses; 2022 Jan; 38(1):50-63. PubMed ID: 33947268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perceptions of HIV cure and willingness to participate in HIV cure-related trials among people enrolled in the Netherlands cohort study on acute HIV infection.
    van Paassen P; Dijkstra M; Peay HL; Rokx C; Verbon A; Reiss P; Prins JM; Henderson GE; Rennie S; Nieuwkerk PT; de Bree GJ
    J Virus Erad; 2022 Jun; 8(2):100072. PubMed ID: 35769632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of Short-Term Antiretroviral Therapy Interruption on Levels of Integrated HIV DNA.
    Strongin Z; Sharaf R; VanBelzen DJ; Jacobson JM; Connick E; Volberding P; Skiest DJ; Gandhi RT; Kuritzkes DR; O'Doherty U; Li JZ
    J Virol; 2018 Jun; 92(12):. PubMed ID: 29593048
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acceptability, motivation and the prospect of cure for people living with HIV and their healthcare providers in HIV cure-focused treatment interruption studies.
    Lau JSY; Smith MZ; Allan B; Martinez C; Power J; Lewin SR; McMahon JH
    AIDS Res Ther; 2020 Nov; 17(1):65. PubMed ID: 33168019
    [TBL] [Abstract][Full Text] [Related]  

  • 16. "I Know That I Was a Part of Making a Difference": Participant Motivations for Joining a Cure-Directed HIV Trial with an Analytical Treatment Interruption.
    Neergaard R; Jones NL; Roebuck C; Rendle KA; Barbati Z; Peterson B; Tebas P; Mounzer K; Metzger D; Montaner LJ; Dube K; Barg FK
    AIDS Res Hum Retroviruses; 2023 Aug; 39(8):414-421. PubMed ID: 35979886
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lessons learned from HIV antiretroviral treatment interruption trials.
    Wen Y; Bar KJ; Li JZ
    Curr Opin HIV AIDS; 2018 Sep; 13(5):416-421. PubMed ID: 29878912
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Strategies for partner notification for sexually transmitted infections, including HIV.
    Ferreira A; Young T; Mathews C; Zunza M; Low N
    Cochrane Database Syst Rev; 2013 Oct; 2013(10):CD002843. PubMed ID: 24092529
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Motivations, barriers and experiences of participants in an HIV reservoir trial.
    De Scheerder MA; van Bilsen WPH; Dullaers M; Martinez-Picado J; Davidovich U; Vandekerckhove L
    J Virus Erad; 2021 Mar; 7(1):100029. PubMed ID: 33598311
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analytical Treatment Interruption in HIV Trials: Statistical and Study Design Considerations.
    Zheng L; Tierney C; Bosch RJ
    Curr HIV/AIDS Rep; 2021 Oct; 18(5):475-482. PubMed ID: 34213731
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.